spacer
home > epc > spring 2002 > stem cells - the clinician's 'philosopher's stone'
PUBLICATIONS
European Pharmaceutical Contractor

Stem Cells - The Clinician's 'Philosopher's Stone'

2001 saw an explosion of interest in stem cells, both in scientific literature and the popular press. Much of this revolved around emotive issues related to manipulation of the pluripotentiality (ability to produce many cell types) of either embryonic or adult stem cells. However, there is still a poor appreciation among the commercial scientific community of the importance of adult tissue stem cells in normal tissue homeostasis and how drugs affect their behaviour. A thorough preclinical evaluation of the effects of potential new drugs on these adult tissue stem cells can reveal mechanisms of action that can significantly improve the efficacy of clinical trials and reduce late stage drug failure.

The Definition and Importance of Stem Cells in Tissue Homeostasis

The fertilised zygote is the ultimate totipotential (capable of making all cell types) stem cell, capable of forming all the differentiated cells and tissues of the body according to strict temporal and spatial controls. The factors that regulate these processes during development are only beginning to be understood. The early divisions of the zygote during development produce further totipotent stem cells and - at least up to the blastocyst stage - cells of the inner cell mass can be isolated, grown and expanded in culture as embryonic stem (ES) cells.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Christopher Potten, Founder of EpiStem Ltd

Professor Christopher Potten is an Emeritus Professor of the UK Cancer Research Campaign, Professor of Stem Cell Biology at Manchester University and a Founder of EpiStem Ltd, a specialist preclinical CRO.

He is a world expert in epithelial stem cell biology and apoptosis, publishing around 400 papers in these areas, and over recent years has assisted many pharmaceutical companies in evaluating their novel anti-cancer and mucositis therapies.

spacer
Professor Christopher Potten
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement